Jeito Capital — 2021 Investments

1 investments dated 2021 · listed companies and verified rows first · show all

Eyebiotecheyebiotech.comAug 2021acquired by Merck

EyeBio (Eyebiotech Limited), a subsidiary of Merck, develops therapies for retinal diseases such as diabetic macular edema and neovascular age-related macular degeneration, targeting vascular leakage through pathways like Wnt signaling.

BiotechHealthtechHolborn, London

David R. Guyer(Founder, CEO & President)Anthony P. Adamis(Chief Scientific Officer, Co-founder, Director & Chair of Advisory Board)James Allister John Costine(Director)Michael Jay Ross(Executive Officer)Catherine Elizabeth Bingham(Director)

Co-investorsSamsara BioCapital Omega Funds SV Health Investors

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.